Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 220

Posts Tagged ‘effect’

“Assessing the Clinical Effect of High Velocity Nasal Insufflation on Improving Ambulation in Patients with Dyspnea: A Feasibility Study”

Posted by fidest press agency su mercoledì, 6 novembre 2019

Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology, today announced that a paper published in the Journal of Clinical Respiratory Diseases and Care, titled “Assessing the Clinical Effect of High Velocity Nasal Insufflation on Improving Ambulation in Patients with Dyspnea: A Feasibility Study” demonstrated that use of Vapotherm Hi-VNI Technology during ambulation is feasible and showed that patients with dyspnea participating in this study who used Hi-VNI Technology as respiratory support walked farther and recovered faster when compared to standard oxygen treatment.The feasibility study was a prospective cross-over trial that compared oxygen treatment as usual (TAU) to treatment with Hi-VNI Technology—which delivers high velocity nasal insufflation (HVNI)—in 28 patients during ambulation in both inpatient and outpatient settings. The goal was to compare how far and for how long patients could ambulate on Hi-VNI Technology versus the standard TAU. Vital signs and recovery time were measured as secondary outcomes. 25 of the 28 patients were analyzed.Among the inpatients in this study, Hi-VNI Technology during ambulation was not only feasible, but also showed improved patient distance walked by 12.4% and duration of time walked by 8.5%. It also improved recovery time by 32.5%. Use was also feasible among outpatients undergoing ambulation, although outpatients performed worse than the inpatient subgroup studied.These results are very encouraging for further research as well as demonstrating feasibility of using Hi-VNI Technology in respiratory patient ambulation.While this study was comparing Hi-VNI Technology to oxygen support, previous studies have demonstrated that Hi-VNI Technology is comparable to noninvasive positive pressure ventilation (NiPPV) when treating patients in undifferentiated respiratory distress. The Vapotherm Transfer Unit is a self contained mobile means of delivering Hi-VNI Technology for patients on the move in the acute setting.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Phase 2 dose-finding study demonstrated the blood pressure lowering effect of aprocitentan

Posted by fidest press agency su martedì, 3 settembre 2019

Allschwil, Switzerland Idorsia Ltd (SIX: IDIA) announced that the results of the Phase 2 study with aprocitentan were presented at the European Society of Cardiology (ESC) 2019 Congress in Paris, France. Hypertension (high blood pressure) is one of the most common cardiovascular risks, and its prevalence continues to rise. According to a recent study, there are more than 1 billion people living with hypertension worldwide. Left uncontrolled, hypertension can lead to life-threatening conditions such as stroke, ischemic heart disease, or kidney disease. Aprocitentan is an orally active dual endothelin receptor antagonist (ERA). Aprocitentan at doses of 12.5 and 25 mg is currently being investigated for the treatment of patients whose blood pressure is uncontrolled despite receiving triple antihypertensive medications (categorized as resistant hypertension) in a global Phase 3 registration study, “PRECISION”. The doses were selected based on a Phase 2 dose-finding study which evaluated the efficacy, safety and tolerability of a once-a-day oral regimen of four dose levels of aprocitentan in patients with essential hypertension. Results of this Phase 2 study were presented at ESC Congress 2019.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Human Reproduction & Embryology

Posted by fidest press agency su venerdì, 18 giugno 2010

Rome Sunday 27 June – Wednesday 30 June 2010 Fiera Via Portuense, 1645-1647 26th Annual Meeting
Monday 28 June (11:45 – in English) Chair: Dr. Luca Gianaroli, ESHRE Chairman • Drs. Srilatha Gorthi and Julie Nekkebroeck: Two studies of women’s attitudes to ‘social egg freezing’ find that   younger and older women have different reasons for delaying motherhood • Dr. Kelechi Nnoaham: Endometriosis has a significant effect on women’s work productivity, first worldwide study finds  Dr. Vivian Rittenberg: Are overweight women undertaking ART more likely to miscarry?
Monday 28 June (13:00 – in Italian) Chair: Dr. Luca Gianaroli, ESHRE Chairman  Dr. Anna Pia Ferraretti: Italian patients amongst the most mobile in crossing borders for ART
• Dr. Paolo Emmanuele Levi Setti: Italian Constitutional Court modifications of a restrictive ART law improve pregnancy rates • Mrs. Filomena Gallo (patient association Amica Cicogna): Italian judges move to protect couples’ rights
Tuesday 29 June (10:00 – in English) Chair: Dr. Anna Veiga, ESHRE Chairman elect • Dr. Maria Lalioti: Researchers discover why some women are sub-fertile and have a poor response to ovarian stimulating hormones • Dr. Suzanna Frints: A cheap and simple, non-invasive blood test could replace invasive diagnostic techniques in early pregnancy • Dr. Cecilia Høst Ramlau-Hansen: Does drinking alcohol during pregnancy affect sperm quality in sons?
Wednesday 30 June (09:15 – in English) Chair: Professor Joep Geraedts, ESHRE past chairman • Dr. Ana Cristina Cobo Cabal: Are on-going pregnancy rates from vitrified eggs as good as those from fresh? New randomised trial has the answer • Dr. Alicia Armstrong: New non-surgical treatment for uterine fibroids can improve quality of life and maintain fertility • Dr. Jacques de Mouzon and Dr. Karl Nygren: Data from the ESHRE European IVF Monitoring Group and world data from the International Committee for Monitoring Assisted Reproductive Technologies (ICMART) http://www.fieraroma.it

Posted in Cronaca/News, Roma/about Rome | Contrassegnato da tag: , , , | Leave a Comment »